BofA/Merrill Lynch Starts Momenta Pharma (MNTA) at Underperform
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Price: $52.48 --0%
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Shares of Momenta Pharmaceuticals (NASDAQ: MNTA) are trading higher heading into the afternoon trading session despite being initiated with an Underperform rating at BofA Merrill earlier.
The stock last traded at $19.84, up 0.85 percent from Monday's closing price.
For more ratings news on Momenta Pharmaceuticals click here and for the rating history of Momenta Pharmaceuticals click here.
The stock last traded at $19.84, up 0.85 percent from Monday's closing price.
For more ratings news on Momenta Pharmaceuticals click here and for the rating history of Momenta Pharmaceuticals click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
- UBS Starts Schrodinger (SDGR) at Neutral
- Raymond James Starts Polaryx Therapeutics (PLYX) at Strong Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
